The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions and groups
The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies and institutions
Lycera Corp., a biopharmaceutical company creating innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research collaboration with Merck, triggering a milestone payment.
The latest staffing and boardroom news from Michigan’s technology-focused companies and institutions
Plymouth-based Lycera Corp., a biopharmaceutical company developing new medicines to treat autoimmune diseases, will present at several industry conferences this fall
Lycera, a biopharmaceutical company and University of Michigan spinoff, plans to partner and collaborate with U-M faculty and students with a move to UM’s North Campus Research Complex.
The Plymouth-based biopharmaceutical developer Lycera Corp. Thursday announced an exclusive research collaboration with pharma giant Merck to develop drug candidates that have the potential to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis